Novo Nordisk
NVO
736 hedge funds and large institutions have $11B invested in Novo Nordisk in 2021 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 259 increasing their positions, 230 reducing their positions, and 46 closing their positions.
86% more call options, than puts
Call options by funds: $65.9M | Put options by funds: $35.4M
76% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 46
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
24% more capital invested
Capital invested by funds: $8.87B → $11B (+$2.16B)
13% more repeat investments, than reductions
Existing positions increased: 259 | Existing positions reduced: 230
4% more funds holding
Funds holding: 707 → 736 (+29)
0.35% more ownership
Funds ownership: 14.49% → 14.85% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
F
Folketrygdfondet
Oslo Norway,
Norway
|
+$36.1M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$31.8M |
| 3 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$21.7M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$21M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$51.6M |
| 2 |
Millennium Management
New York
|
-$26.3M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$21.5M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$21.2M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$18.8M |
NVO Hedge Fund Activity: Q2 2021 in Review
736 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2021, worth a combined $11B — up 24% from $8.87B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new NVO positions and 46 closed out — a net gain of 35 holders — while 259 added to existing stakes and 230 trimmed.
The largest buyer was Folketrygdfondet, adding an estimated $36.1M. The largest seller was Renaissance Technologies, cutting an estimated $51.6M.
- 736 institutional investors held Novo Nordisk (NVO) as of Q2 2021, up from 707 in Q1 2021.
- Funds reported $11B of Novo Nordisk stock for Q2 2021, up 24% quarter-over-quarter.
- 81 funds opened new Novo Nordisk positions in Q2 2021 and 46 closed out, a net change of +35 holders.
- The largest Novo Nordisk buyer in Q2 2021 was Folketrygdfondet, an estimated $36.1M added.
- The largest Novo Nordisk seller in Q2 2021 was Renaissance Technologies, an estimated $51.6M sold.
Based on aggregated 13F filings for Q2 2021.